Major Pharmaceuticals memantine extended-release capsules fail dissolution specifications
Major Pharmaceuticals is recalling one lot of Memantine Hydrochloride Extended-Release Capsules, 7 mg, after the product failed dissolution specifications.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a failed dissolution specification, which can alter the rate of drug release and creates a risk of harm with no injuries reported.
Plain-English summary
Major Pharmaceuticals is recalling Memantine Hydrochloride Extended-Release Capsules, 7 mg, supplied as 100 capsules in 10 x 10 blister packs, NDC 0904-6734-61.
The stated reason is failed dissolution specifications. Dissolution testing measures how a capsule releases its active ingredient, and an extended-release formulation that falls outside specification may not deliver the drug at the intended rate. The FDA classified the action as Class II.
The affected lot is N02425, expiry 05/31/2027. Distribution was US nationwide.
This is a prescription medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding the affected lot should contact their pharmacy or prescriber about a replacement supply.
The recalled product
- Product
- MEMANTINE HYDROCHLORIDE (MEMANTINE HYDROCHLORIDE)
- Brand
- MEMANTINE HYDROCHLORIDE
- Manufacturer
- The Harvard Drug Group LLC
- Category
- Drug — Extended-release capsule
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # N02425
- Exp Date: 05/31/2027.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · MEMANTINE HYDROCHLORIDE
- ModerateMemantine Hydrochloride Extended-Release Capsules Recalled for Dissolution Failures
FDA (Drugs) · 2020-05-20
- LowMemantine Hydrochloride Extended-Release Capsules Recalled for Dissolution Failure
FDA (Drugs) · 2020-02-26
- ModerateLupin Recalls Memantine Hydrochloride Capsules for Dissolution Failure
FDA (Drugs) · 2020-02-19
- ModerateLupin Recalls Memantine Hydrochloride Capsules Due to Dissolution Failure
FDA (Drugs) · 2019-12-25
Same manufacturer · The Harvard Drug Group LLC
See all →- ModerateMETHYLERGONOVINE MALEATE Tablets 0.2 mg Drug Recall
FDA (Drugs) · 2026-07-01
- ModerateOmega-3-Acid Ethyl Esters capsules recalled for failed capsule specifications
FDA (Drugs) · 2026-04-29
- ModerateMidodrine hydrochloride tablets recalled over inadequately sealed blister packaging
FDA (Drugs) · 2026-03-11
- ModerateGabapentin blister packs recalled after unknown impurity exceeded specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsules recalled after stability testing found unknown impurity out of specification
FDA (Drugs) · 2025-10-29
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15